Novartis pauses autoimmune cell therapy trials after three patient deaths
Novartis temporarily paused trials of an experimental cell therapy for autoimmune diseases after three patients died. Separately, Novartis shares rose 5.3% premarket following positive Phase III trial data for its multiple sclerosis drug remibrutinib, which reduced relapse rates, cut MRI brain lesions, and delayed disability progression.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@business
Novartis temporarily paused trials of an experimental cell therapy for autoimmune diseases after three patients died https://t.co/AfeTv0vv8Z
@schaeffers
Novartis $NVS +5.3% before the bell, after positive trial data for the company’s multiple sclerosis drug. It looks like the $160 level will continue to keep a lid on today's gains, however. Year to date, the equity is up 10.3%.
@schaeffers
Novartis $NVS +4% premarket after a big Phase III win in multiple sclerosis! Its oral drug remibrutinib: → Reduced relapse rates → Cut MRI brain lesions → Delayed disability progression Global regulatory filings are next.